tbuckley/cabot-search huggingface dataset:
Abstract 2382: <i>SOX17</i> promoter methylation in CTC and cell free DNA isolated from plasma of breast cancer patients
Authors: Maria Chimonidou, Areti Strati, Nikos Malamos, Vasilis Georgoulias, Evi S. Lianidou
Journal: Cancer Research (2012)

Abstract Introduction: Molecular characterization of Circulating Tumor Cells (CTC) is a hot topic nowadays. SOX17 plays a very critical role in the regulation of development and stem/precursor cell function, at least partly through repression of Wnt pathway activity. Silencing of SOX17 due to its promoter methylation is a frequent event and may contribute to aberrant activation of Wnt signaling in breast cancer. We have recently shown that the promoter of this gene is methylated in CTC (Chimonidou et al, Clin Chem 2011). The aim of the present study was to evaluate whether SOX17 promoter methylation in CTC, is associated with the methylation pattern of this gene in matched cell free DNA isolated from plasma of breast cancer patients. Patients and methods: We firstly developed a highly sensitive and specific Methylation Specific Real-time PCR method for SOX17. The methylation status of SOX17 was examined in paired specimens of DNA isolated from CTC and cell free DNA (cfDNA) circulating in plasma of the same individuals. 58 patients with operable breast cancer, 21 patients with verified metastasis, and 12 healthy individuals used as controls were enrolled in our study. For CTC analysis, DNA was extracted from EpCAM positive immunomagnetically isolated CTC fraction, while cfDNA was isolated from 200μL of plasma from the same individuals. DNA extracted from isolated CTC and cfDNA was modified by a Sodium Bisulfite (SB) conversion reaction and subjected to methylation specific real time PCR. Results: In CTC, promoter methylation of SOX17 was observed in 22/58 (37.9%) of patients with operable breast cancer, 12/21 (57.1%) of patients with verified metastasis and 1/12 (8.3%) of healthy individuals. In the matched plasma samples, promoter methylation of SOX17 was observed in 23/58 (39.6%) of patients with operable breast cancer, 11/21 (52.4%) of patients with verified metastasis and 1/12 (8.3%) in healthy individuals. By comparing these results we found that promoter methylation of SOX17 in CTC was significantly correlated with promoter methylation of SOX17 in cell free DNA isolated from plasma of the same patients (P&amp;lt;0.005). Conclusion: We show for the first time that promoter methylation of SOX17 in CTC, is associated with the methylation pattern of this gene in matched cell free DNA isolated from plasma of breast cancer patients. Our findings suggest a new dimension to the origin of cell free DNA and indicate a correlation between cell free DNA and CTC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2382. doi:1538-7445.AM2012-2382
Abstract 3521: RECRUIT-TandAb AFM13: Overcoming limitations of monoclonal antibodies in Hodgkin lymphoma
Authors: Erich Rajkovic, Stefan Knackmuss, Uwe Reusch, Achim Rothe, Max Topp, Anas Younes, Miroslav Ravic, Christian Hucke, Eugene Zhukvosky, Melvyn Little
Journal: Cancer Research (2012)

Abstract Introduction: AFM13 is a RECRUIT-TandAb (CD30xCD16A) for treating Hodgkin Lymphoma by recruiting NK-cells and macrophages to the specific CD30 surface antigen on Reed-Sternberg cells. This redirected immune response leads to potent tumor cell killing. RECRUIT TandAbs are tetravalent and bispecific, and address key deficiencies of monoclonal antibodies such as (i) V/F polymorphism and (ii) non-selective binding to immune effector cells vs. granulocytes via CD16B receptor. Furthermore, RECRUIT-TandAbs have significant advantages over other antibody fragment technologies such as (i) bivalent binding to the targets and, (ii) longer half-life. Methods: AFM13 binds with high affinity to both CD30 and CD16A and is able to rapidly induce the lysis of CD30+ cells at picomolar concentrations in the presence of PBMCs. Intensive in vitro characterization demonstrated that AFM13 is specific for the CD16A receptor, which becomes activated only in the presence of tumor cells: there is no systemic activation of NK-cells in the absence of target cells. A robust GMP production process in mammalian cells and a lyophilized formulation with excellent stability have been established. Toxicology testing in Cynomolgus monkeys did not reveal any toxicity. Currently, AFM13 is being investigated in a single arm phase I dose escalation trial for patients with relapsed and/or refractory Hodgkin Lymphoma (HL). Patients receive a single cycle of 4 weekly doses, which are escalated in cohorts of 3 patients at the dose levels of 0.01, 0.04, 0.15, 0.5, 1.5, 4.5 and 7.0 mg/kg. Study objectives are the assessment of safety and tolerability, PK, immunogenicity, antitumor activity, as well as the determination of the maximum tolerated dose (MTD) or the optimal biological dose (OBD). The safety of the MTD or OBD will be confirmed in further patients receiving 2 cycles of AFM13. Results and Conclusion: So far, AM13 was shown to be safe and well tolerated by highly pre-treated Hodgkin Lymphoma patients in weekly doses of up to 1.5mg/kg. Adverse events were generally mild, with the most frequent drug-related event being fever. A first objective response was achieved on the dose level 1.5mg/kg. Five cases of stable disease / minor response were observed on lower dose levels. Further patients are being treated in the ongoing dose escalation study. Preclinical and interim clinical data will be presented, showing that AFM13 may become a safe and effective targeted therapy for CD30 positive malignancies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3521. doi:1538-7445.AM2012-3521
Mice lacking the glutamate-cysteine ligase modifier subunit are susceptible to myocardial ischaemia–reperfusion injury
Authors: Tsuyoshi Kobayashi, Yosuke Watanabe, Yukio Saito, Daisuke Fujioka, Takamitsu Nakamura, Jun-ei Obata, Yoshinobu Kitta, Toshiaki Yano, Kenichi Kawabata, Kazuhiro Watanabe, Hideto Mishina, Sadahiro Ito, Kiyotaka Kugiyama
Journal: Cardiovascular Research (2009)

AimsGlutamate-cysteine ligase (GCL), a rate-limiting enzyme for glutathione (GSH) synthesis, is composed of catalytic and modifier subunits. This study examined the pathogenic role of GCL modifier subunits (GCLM) in myocardial ischaemia–reperfusion (I/R) injury using mice lacking the GCLM (GCLM−/−).
Anaphylactoid Reaction to Nitrofurantoin
Authors: Albert A. Fisk
Journal: New England Journal of Medicine (1957)

NITROFURANTOIN (Furadantin) has become increasingly useful in the treatment of resistant urinary-tract infections and is now widely employed. Nitrofurazone (Furacin), which is used topically in chronic skin infections, is known to be associated with frequent skin sensitivity reactions, but reactions to nitrofurantoin, other than gastrointestinal symptoms, have not been widely reported. Severe anaphylactoid reactions of the type described below are not recorded in the literature. Stewart and Rowe1 reported 12 per cent reactions, mostly gastrointestinal, in a review of 107 patients. One patient required hospitalization for dermatitis medicamentosa, and 1 had a "slight sensation of pressure in the rectum and . . .
Roles of retinoids and their nuclear receptors in the development and prevention of upper aerodigestive tract cancers.
Authors: R Lotan
Journal: Environmental Health Perspectives (1997)

Vitamin A analogs (retinoids) suppress oral and lung carcinogenesis in animal models and prevent the development of second primary tumors in head, neck, and lung cancer patients. These effects result from changes in the expression of genes that regulate cell growth and differentiation. Retinoic acid receptors (RARs; -alpha, -beta, and -gamma) and retinoid X receptors (RXRs; -alpha, -beta, and, -gamma) are retinoid-activated transcription factors, which mediate effects of retinoids on gene expression. Therefore, alterations in receptor expression or function could interfere with the retinoid signaling pathway and thereby enhance cancer development. We found that the expression of RAR beta was suppressed in more than 50% of oral and lung premalignant lesions in individuals without cancer and in dysplastic lesions adjacent to cancer and in malignant oral and lung carcinomas. The expression of the other receptors was not different among normal, dysplastic, and malignant oral tissues. However, the expression of RAR gamma and RXR beta was somewhat decreased in lung cancers. These results show that RAR beta expression is lost at early stages of carcinogenesis in the aerodigestive tract and support the hypothesis that the loss of RAR beta expression may facilitate the development of some of these cancers.
Low Renin Hypertension
Authors: J C Gunnells, W L McGuffin
Journal: Annual Review of Medicine (1975)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), emerged in China in December 2019 and quickly spread around the globe, killing more than 4 million people and causing a severe economic crisis. ...Read More
RÉSUMÉ OF SKIN DISEASES MOST COMMONLY SEEN IN GENERAL PRACTICE
Authors: EVERETT C. FOX
Journal: JAMA (1949)

Crocker, Buckley, Pollitzer, Alderson and Reich, Gilman and other observers have presented interesting statistical studies of the incidence of common diseases of the skin. Goodman<sup>1</sup>and Sohrweide<sup>2</sup>have published statistical studies on more than 1,000,000 dermatologic diagnoses made in private and clinical practice. In these series of reports six common dermatoses have accounted for 44 to 64 per cent of all diagnoses. There have been some variations of the six most common dermatoses. Eczema and acne were the two most frequent diagnoses and usually represented about 30 per cent of the cases. In more recent years tinea (fungous infections) and dermatitis venenata (eczematous contact dermatitis) have become much more frequent diagnoses. These changes have occurred as more accurate diagnoses of the fungous infections were made and as atopic dermatitis, contact dermatitis and the occupational dermatoses were recognized and removed from the eczema group. Sulzberger and Baer<sup>3</sup>stated,
Cancer Risk From Multiple Imaging Tests
Authors: Daniel J. Durand
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Agreement among 3 Methods to Measure Corneal Thickness: Ultrasound Pachymetry, Orbscan II, and Visante Anterior Segment Optical Coherence Tomography
Authors: Emmy Y.M. Li, Shaheeda Mohamed, Christopher K.S. Leung, Srinivas K. Rao, Arthur C.K. Cheng, Carol Y.L. Cheung, Dennis S.C. Lam
Journal: Ophthalmology (2007)
Gene Therapy and Vein Graft Patency in Coronary Artery Bypass Graft Surgery
Authors: Vincent R. Conti, Glenn C. Hunter
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Impaired Stimulation of p38α-MAPK/Vps41-HOPS by LPS from Pathogenic Coxiella burnetii Prevents Trafficking to Microbicidal Phagolysosomes
Authors: Abdoulaye Oury Barry, Nicolas Boucherit, Giovanna Mottola, Pavol Vadovic, Virginie Trouplin, Philippe Soubeyran, Christian Capo, Stefano Bonatti, Angel Nebreda, Rudolf Toman, Emmanuel Lemichez, Jean-Louis Mege, Eric Ghigo
Journal: Cell Host & Microbe (2012)
A rapid method of haplotyping HFE mutations and linkage disequilibrium in a Caucasoid population
Authors: C G Mullighan, M Bunce, G C Fanning, S E Marshall, K I Welsh
Journal: Gut (1998)

HFE mutations are associated with hereditary haemochromatosis. However, a simple method capable of demonstrating the cis/trans arrangement of alleles is lacking, and linkage disequilibrium between HFE alleles and classic HLA loci is unknown. These are important issues as the pathogenic role of the mutations is not known.To develop a simple method of genotyping HFE mutations suitable for clinical use in addition to large disease studies.A total of 330 Caucasoid cadaveric organ donor controls were examined. Ten individuals previously HLA-H genotyped by polymerase chain reaction using restriction fragment length polymorphism (PCR-RFLP) were also examined to validate the method.A simple polymerase chain reaction using sequence specific primers (PCR-SSP) capable of haplotyping the mutations was developed. HFE allele and haplotype frequencies and linkage disequilibrium with eight HLA class I and II loci were examined in the control population.27% and 19.7% of patients were positive for the 63D and 282Y alleles, respectively. No chromosome carried both 63D and 282Y. Linkage disequilibrium between 282Y and HLA-A*03 was confirmed, but was not straightforward: some A*03-associated alleles (DRB1*15, DQB1*06), but not all (B*07, Cw*0702), were associated with 282Y.Linkage disequilibrium data suggest that an HLA-B*07 containing haplotype contains an element affording protection from haemochromatosis and may suggest the timing of the founder 282Y mutation.
Atopy and bronchial reactivity in older patients with cystic fibrosis.
Authors: M J Tobin, O Maguire, D Reen, E Tempany, M X Fitzgerald
Journal: Thorax (1980)

We studied 25 adolescent and adult patients with cystic fibrosis (CF) and 25 control subjects to determine if the prevalence of atopy and bronchial hyperreactivity was increased in this disease. Results showed that atopic symptoms, as defined by history, were more frequently present in the CF patients. Prick testing of the skin produced positive reactions in 88% of the CF group and 36% of the control subjects (p less than 0.001), and the mean number of reactions per subject was significantly higher in the former group (p less than 0.001); reactions to fungal antigens were strikingly positive in the CF group. The CF patients had a significantly higher mean serum IgG4 (p less than 0.001), IgE (p less than 0.01), and higher mean eosinophil count (p less than 0.05). Clear-cut bronchial hyperreactivity was demonstrated in the CF group compared with control subjects. Bronchial provocation with 400 micrograms of histamine led to a greater than 15% fall in the preinhalation FEV1 in 35% of the CF subjects compared with 4% of the control group, with a mean percentage fall of 15% and 3% respectively (p less than 0.001). In the CF group a greater than 15% rise in PEFR occurred in 32% after inhalation of the parasympatholytic, ipratropium bromide (54 micrograms), and in 27% after inhalation of the sympathomimetic, fenoterol (400 micrograms). No correlation was found between bronchial reactivity and atopic status, HLA phenotype pattern, or disease severity. The cause of the increased prevalence of atopy and bronchial reactivity in CF patients remains unknown. However, it is clear that a trial of bronchodilator therapy is warranted in adolescents and young adults with CF.
Prognosis of the chronic liver diseases in the “health” population
Authors: V. Čolić-Cvrlje, S. Čerlek, A. Čolić, S. Naumovski-Mihalić, B. Cvjetičanin, M. Katičić, M. Prskalo, M. Dominis, B. Šabariċ, B. Papa
Journal: Journal of Hepatology (2001)
Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and <i>N</i> -acetyl glucosamine: results of a randomized, double-blind, vehicle-controlled trial
Authors: A.B. Kimball, J.R. Kaczvinsky, J. Li, L.R. Robinson, P.J. Matts, C.A. Berge, K. Miyamoto, D.L. Bissett
Journal: British Journal of Dermatology (2009)

Journal Article Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and N‐acetyl glucosamine: results of a randomized, double‐blind, vehicle‐controlled trial Get access A.B. Kimball, A.B. Kimball Harvard Medical School, Boston, MA 02114, U.S.A. Alexa B. Kimball. E‐mail: harvardskinstudies@partners.org Search for other works by this author on: Oxford Academic Google Scholar J.R. Kaczvinsky, J.R. Kaczvinsky The Procter & Gamble Company, Cincinnati, OH, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar J. Li, J. Li The Procter & Gamble Company, Cincinnati, OH, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar L.R. Robinson, L.R. Robinson The Procter & Gamble Company, Cincinnati, OH, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar P.J. Matts, P.J. Matts The Procter & Gamble Company, Egham, Surrey, U.K. Search for other works by this author on: Oxford Academic Google Scholar C.A. Berge, C.A. Berge The Procter & Gamble Company, Cincinnati, OH, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar K. Miyamoto, K. Miyamoto The Procter & Gamble Company, Cincinnati, OH, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar D.L. Bissett D.L. Bissett The Procter & Gamble Company, Cincinnati, OH, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 162, Issue 2, 1 February 2010, Pages 435–441, https://doi.org/10.1111/j.1365-2133.2009.09477.x Published: 01 February 2010
Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial
Authors: Jonathan Mant, David A Fitzmaurice, F D Richard Hobbs, Sue Jowett, Ellen T Murray, Roger Holder, Michael Davies, Gregory Y H Lip
Journal: BMJ (2007)

<b>Objective</b> To assess the accuracy of general practitioners, practice nurses, and interpretative software in the use of different types of electrocardiogram to diagnose atrial fibrillation. <b>Design</b> Prospective comparison with reference standard of assessment of electrocardiograms by two independent specialists. <b>Setting</b> 49 general practices in central England. <b>Participants</b> 2595 patients aged 65 or over screened for atrial fibrillation as part of the screening for atrial fibrillation in the elderly (SAFE) study; 49 general practitioners and 49 practice nurses. <b>Interventions</b> All electrocardiograms were read with the Biolog interpretative software, and a random sample of 12 lead, limb lead, and single lead thoracic placement electrocardiograms were assessed by general practitioners and practice nurses independently of each other and of the Biolog assessment. <b>Main outcome measures</b> Sensitivity, specificity, and positive and negative predictive values. <b>Results</b> General practitioners detected 79 out of 99 cases of atrial fibrillation on a 12 lead electrocardiogram (sensitivity 80%, 95% confidence interval 71% to 87%) and misinterpreted 114 out of 1355 cases of sinus rhythm as atrial fibrillation (specificity 92%, 90% to 93%). Practice nurses detected a similar proportion of cases of atrial fibrillation (sensitivity 77%, 67% to 85%), but had a lower specificity (85%, 83% to 87%). The interpretative software was significantly more accurate, with a specificity of 99%, but missed 36 of 215 cases of atrial fibrillation (sensitivity 83%). Combining general practitioners9 interpretation with the interpretative software led to a sensitivity of 92% and a specificity of 91%. Use of limb lead or single lead thoracic placement electrocardiograms resulted in some loss of specificity. <b>Conclusions</b> Many primary care professionals cannot accurately detect atrial fibrillation on an electrocardiogram, and interpretative software is not sufficiently accurate to circumvent this problem, even when combined with interpretation by a general practitioner. Diagnosis of atrial fibrillation in the community needs to factor in the reading of electrocardiograms by appropriately trained people.
Improvement in quality of life post circular mapping guided pulmonary vein isolation in both normal heart and low ejection fraction patients
Authors: Dianna Bash, Scott Rosenberg, Nassir F. Marrouche, Jens Guenther, Volker Schibgilla, Ahmad Abdul-Karim, Sharat Koul, Oussama Wazni, Mustafasahin Shaaraoui, David Martin, Alejandro Perez-Lugones, Walid Saliba, Robert Schweikert, Eduardo Saad, Johannes Brachmann, Andrea Natale
Journal: Journal of the American College of Cardiology (2003)
Fatigue: time to recognise and deal with an old problem
Authors: A.-M. Feyer
Journal: BMJ (2001)

Papers p 829 

Being awake at times that are biologically programmed for sleep, prolonged wakefulness, and having had restricted sleep over a period of time result in fatigue and sleepiness. These conditions undoubtedly adversely affect human performance. This week's issue includes another reminder of the dangers of sleepiness while driving,1 yet we continue to fail to treat fatigue with the seriousness it deserves.

The impact of sleep loss on performance is well documented by laboratory research.2 Even modest amounts of sleep loss over short periods (about two hours a night over one week) accumulate and manifest themselves as an irresistible tendency to fall asleep during inappropriate or dangerous situations, like driving.3 The vulnerability of performance to circadian rhythm in alertness and sleepiness, even in well rested individuals, is similarly well documented.2 Data on accidents from a variety of sources worldwide confirm the impact of time of day on the occurrence of accidents.4 Working at night, and working hours that restrict sleep opportunity, have long been implicated in compromised safety at work.5

The size of the problem is significant. A survey of car drivers in the United Kingdom found …